- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05897840
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients (SoVHIRR)
Acute kidney injury (AKI) is common in intensive care unit (ICU) and inducing a high morbidity and mortality. In severe forms of AKI (more than 25% of AKI patients admitted to the ICU), renal replacement therapy (RRT) is often necessary. Although RRT is a cornerstone of therapy, it can lead to serious adverse effects, such as intradialytic arterial hypotension. Indeed, arterial hypotension during the session - intra-dialytic arterial hypotension (IDH) - occurs frequently complication and so regardless of the RRT modality used. Its occurrence may worsen significantly the outcome as previously reported. It is therefore of parmount importance to prevent such an adverse effect.
The investigators hypothesize that a decrease in the central venous oxygen saturation (SvcO2) measured related to a decreased cardiac output could precede the onset of IDH. The aim of this study is collect IDH in AKI patients and to measure continuously SvcO2 during RRT session in order to investigate its role in predicting IDH.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In ICU settings, about 25% of AKI patients underwent RRT. RRT leads to certain complications, the most frequent and severe of which is IDH. The frequency of IDH varies from 10 to 70% and from 19 to 43% in intermittent and continuous RRT respectively.
The occurrence of IDH worsens the prognosis of critically ill patients. It may impair the recovery of renal function and is associated with increased mortality. Thus, early detection of IDH requires the development of preventive strategies and the implementation of adapted curative therapies.
IDH results from several mechanisms. The main mechanisms involved is hypovolemia leading to cardiac dysfunction, but also cardiac dysfunction not related to hypovolemia.
The identification of tools correlated with cardiac output could allow early prediction of IDH. Yet, no tool has been evaluated to predict the occurrence of IDH.
Central venous oxygen saturation (SvcO2) is a reflection of the balance between systemic O2 transport and tissue O2 consumption and thus is the indicator of cardiac output. A decrease in cardiac output leads to a decrease in SvcO2 to enhance O2 transport and to maintain arterial pressure. Assuming that O2 extraction is constant, SvcO2 would then be a surrogate for cardiac output. A decrease in SvcO2 may reflect a decrease in cardiac output before IDH occurs.
There are very few data in the literature evaluating changes in cardiac output during an RRT session. Continuous measurement of SvcO2, a minimally invasive and indirect marker of cardiac output, during an RRT session has never been reported to predict IDH.
The investigators hypothesize that a decrease in SvcO2, indicative of decreased cardiac output, should precede the onset of IDH.
In order to evaluate this hypothesis, the investigators intend to measure continuous SvcO2 and continuous cardiac output during the first three RRT sessions, regardless of the RRT modality.
The investigators will assess the performance of SvcO2 values and other invasive hemodynamic parameters in predicting the occurrence of IDH using ROC curves. Once the composite score has been constructed, an optimal threshold will be determined using Youden's J statistic. Determination of the 95% confidence interval (95% CI), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Comparison of areas under the curve using Delong's non-parametric approach.
Patients will be monitored until they are discharged from intensive care, intensive care, death or D28 max.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eddine BENDIAB, Dr
- Phone Number: +33 0467332495
- Email: e-bendiab@chu-montpellier.fr
Study Contact Backup
- Name: Kada KLOUCHE, Pr
- Phone Number: +33 0467338441
- Email: k-klouche@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France, 34295
- Recruiting
- UH of Montpellier
-
Contact:
- Eddine BENDIAB, Dr
- Phone Number: +33 0467332495
- Email: e-bendiab@chu-montpellier.fr
-
Contact:
- Kada KLOUCHE, Pr
- Phone Number: +33 0467338441
- Email: k-klouche@chu-montpellier.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Critically ill patients requiring blood pressure monitoring
- Severe AKI treated by RRT
- Hemodynamic stability prior to initiation of RRT
- Patients aged above 18 years
Exclusion Criteria:
- Pregnancy
- Major under tutorship or curatorship
- Refusal of the patient or trusted person/family (if present) to sign the informed consent or to confirm participation in the case of emergency inclusion
- Patient is not beneficiary or affiliated with a social security plan
- Contraindication to placement of a venous catheter in the superior vena cava territory: thrombosis of the superior vena cava, thrombosis of the jugular and subclavian veins
- Chronic end-stage renal failure on chronic dialysis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Continuous measurement of central venous oxygen saturation
The measurement of SvcO2 is performed by spectrophotometry which is a quantitative measurement of wavelength transmission. For this, a fiber optic probe, CeVOX probe, is used. |
Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Venous oxygen saturation measurement
Time Frame: 1-28 days
|
Venous oxygen saturation measured continuously during the RRT session in the critically ill patient. Intradialytic hypotension is defined as the occurrence of a decrease in systolic blood pressure below 90mmHg and/or a decrease in mean arterial pressure below 65mmHg that warrants therapeutic intervention (vascular filling, introduction or increase in the dose of vasopressor by more than 25% to maintain satisfactory blood pressure, discontinuation of ultrafiltration) during the RRT session. |
1-28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of IDH during a RRT session
Time Frame: 1-28 days
|
Number of IDH during a RRT session
|
1-28 days
|
IDH corrective measures
Time Frame: 1-28 days
|
Vascular filling, introduction or increase of the dose of vasopressor by more than 25% to maintain satisfactory blood pressure, discontinuation of ultrafiltration
|
1-28 days
|
Cardiac output variation
Time Frame: 1-28 days
|
Variations in cardiac output measured continuously during the RRT session
|
1-28 days
|
Pulse pressure variation
Time Frame: 1-28 days
|
Value of the pulse pressure variation measured continuously during the RRT session
|
1-28 days
|
RRT duration
Time Frame: 1-28 days
|
RRT duration
|
1-28 days
|
Mortality in the ICU
Time Frame: 1-28 days
|
Mortality in the ICU
|
1-28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eddine BENDIAB, Dr, Hospital of Montpellier
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL20_0411
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Chinese PLA General HospitalBeijing Tsinghua Changgeng HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Chinese PLA General HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Ain Shams UniversityRecruiting
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
Clinical Trials on Fiber-optic probe CeVOX
-
BraindexRecruitingPost-Operative ConfusionFrance
-
National Institute of Arthritis and Musculoskeletal...Completed
-
Nathalie CharpakHospital Universitario San IgnacioCompletedPhototherapy | Jaundice, NeonatalColombia
-
Duke UniversityWallace H. Coulter FoundationCompletedCancer of the Cervix, Cancer of the EndometriumUnited States
-
University of FlorenceCareggi Hospital; Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa,... and other collaboratorsRecruitingUrinary Bladder Cancer | Urothelial Carcinoma | Urinary Tract CancerItaly
-
ivWatch, LLCCompletedInfiltration of Peripheral IV TherapyUnited States
-
Mansoura UniversityRecruiting
-
ivWatch, LLCCompletedInfiltration of Peripheral IV TherapyUnited States
-
Concordia Laboratories Inc.CompletedNon-small Cell Lung Cancer (NSCLC) | Lung MetastasisUnited States, Canada
-
Concordia Laboratories Inc.Completed